Belvedere Trading’s Quince Therapeutics QNCX Stock Holding History

Belvedere Trading’s Portfolio QNCX Stock Details QNCX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-65	Closed	-$1.32K	–	1170
2026 Q1	$1.32K	Buy	+65	New	+$13K	﹤0.01%	715

Other funds holding QNCX

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

SCM

Squadron Capital Management Westmont, Illinois $322M AUM

Shay Capital New York $1.56B AUM 46.17% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

CAM

Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Belvedere Trading's QNCX Position: Q2 2026 in Review

Belvedere Trading sold out of Quince Therapeutics (QNCX) in Q2 2026, closing a stake of 65 shares — an estimated $1.32K sold.

Belvedere Trading first reported a position in QNCX in Q1 2026 and held it in 1 quarter. The position peaked at $1.32K in Q1 2026. 27 funds tracked by Wall St. Rank hold QNCX as of Q2 2026.

Belvedere Trading reported no remaining Quince Therapeutics position as of Q2 2026 after selling out during the quarter.
Belvedere Trading sold 65 Quince Therapeutics shares in Q2 2026, an estimated $1.32K.
Belvedere Trading first reported a position in Quince Therapeutics in Q1 2026 and held it in 1 quarter.
Belvedere Trading's Quince Therapeutics position peaked at $1.32K in Q1 2026.
27 funds tracked by Wall St. Rank held Quince Therapeutics as of Q2 2026.

Based on Belvedere Trading's 13F filing for Q2 2026, filed 31 Jul 2026.